	MIC_{50} (μM)	MBC_{90} (μM)	CC_{50} _BHK21 (μM)	CC_{50}_HepG2 (μM)	CC_{50}_C6 glioma (μM)
Compound 5 	**0.65±0.11**	**2.5-5**	**>50**	**>50**	**>50**
Compound 6 	**0.63±0.24**	**2.5-5**	**13.75±0.87**	**19.3±8.0**	**8.10±1.55**
Compound 7 	**0.11±0.04**	**1.25-2.5**	**3.75±0.35**	**4.50±0.28**	**>12.5**
Compound 8 	**9.67±1.45**	**n.d.**	**>50**	**>50**	**>50**
Compound 9 	**>20**	**n.d.**	**n.d.**	**n.d.**	**n.d.**

Supplementary table S1. Initial structure-activity relationship of PI compounds. The inhibitory activity (MIC_{50}) was determined against *M. tuberculosis* H37Rv. The cidal activity (MBC_{90}) and cytotoxicity (CC_{50}) were determined after 5 days of exposure to a single dose of compound. Assays were carried out at least two times. MIC_{50}: Minimum Inhibitory Concentration 50%; MBC_{90}: Minimum Bactericidal Concentration 90%, CC_{50}: Cyototoxic concentration 50%. n.d.: not determined.

	***M. tuberculosis* strain**							
Glycerol:	**AH9584** MIC (μM)		**BE11677** MIC (μM)		**E8133** MIC (μM)		**W4** MIC (μM)	
	+	-	+	-	+	-	+	-
Compound 1	0.43	> 20	1.09	> 20	0.67	> 20	0.07	> 20
Compound 2	0.44	> 20	1.21	> 20	0.63	> 20	0.06	> 20
Rifampicin	0.005	0.008	0.022	0.022	0.016	0.016	<0.005	0.016
Isoniazid	0.19	0.19	0.20	0.23	0.08	0.08	<0.005	0.14

Supplementary table S2. Activity of the PI compounds against four recent clinical isolates. The MIC_{50} of compound 1 and 2 was tested in the presence (+) or absence (-) of glycerol. Rifampicin and isoniazid were used as reference compounds. The assay was repeated two times independently.